Drs. Feldman and Goutman call for action to study how the environment influences ALS risk and progression in a JAMA Neurology article. Dr. Feldman recently received a $2.5 million grant from the NIH to examine the ties between genetics and the environment.
A new study by Brian Callaghan, M.D., M.S., finds higher out-of-pocket costs lead to neurology patients being less likely to take their prescribed medications.
Medicine at Michigan's Winter 2020 magazine featured Dr. Eva Feldman for receiving the Distinguished Alumni Achievement Award.
Dr. Feldman points out that at least 50% of diabetics suffer from nerve pain and explains what lifestyle changes can be made to limit nerve damage.
In 2019, our laboratory made discoveries in diabetes, Alzheimer's disease and ALS, which resulted in 21 scientific manuscripts. 2020 will mark the 20th anniversary of the Program for Neurology Research & Discovery.
December 6 marked the fourth annual University of Michigan Hockey ALS Awareness Game. Drs. Stephen Goutman and Eva Feldman joined former patient Scott Matzka's children for the ceremonial faceoff.
Drs. Eva Feldman and Zach Simmons, who direct the multidisciplinary ALS clinics at U-M, PSU, respectively, discuss their history together and their work in ALS
Bioinformatics & Transitioning to the US from Yemen’s Civil War.
Drs. Figueroa-Romero and Murdock authored a paper that found an association between gut bacteria and the immune system during ALS progression in a mouse model.
Diabetes has reached epidemic proportions. In the United States, over 30 million people have diabetes, while another 85 million have prediabetes. These numbers are projected to increase at the rate of 5% per year. At this pace, more than one in three Americans born after 2000 will develop diabetes in their lifetime.
Autoimmune Neuropathy + A Wolverine Returns Home from Buckeye Country
The National Institute of Diabetes & Digestive and Kidney Diseases (NIDDK)-sponsored grant will fund research looking into the therapeutic potential for a new mechanism-based approach in diabetic neuropathy.
The University of Michigan Institute for Clinical & Health Research (MICHR) honored Dr. Eva Feldman for her legacy of fostering the intellectual, creative, scholarly and professional growth of their students, fellows and trainees in the areas of clinical and translational health and research.
The ALS grant will fund the study of NK cells’ relationship to ALS and work to push a new drug therapy into clinical trials.
Fredrik Kristensen, a student at Denmark's Aarhus University, spent the fall in the lab of the Program for Neurology Research & Discovery as a visiting researcher examining diabetes with Dr. Brian Callaghan.
Dr. Goutman will use the three-year ALS Association grant to consider how genetic factors and environmental pollutants jointly affect ALS development and progression in patients.
Dr. Bhumsoo Kim's research indicates that Insulin-resistance, a telltale characteristic of diabetes, affects the treatment of Alzheimer’s disease.
Dr. Eva Feldman discusses the great impact that the American Neurological Association has had on her career. She served as ANA President from 2011-13 and believes that it is the home for all academic neurologists, both established and emerging.
PNRD Research on Diabetic Neuropathy chosen as 6 “Highlights of the Meeting,” out of submissions by over 800 of the nation’s top neurologists at the American Neurological Association’s Annual meeting.
Eva Feldman, M.D., Ph.D., organized a delegation from the American University of Beirut that included President Fadlo Khuri, M.D., three deans and other scientific leaders from the Lebanon-based institution.
